Loading viewer...
investor_presentation
Format: PDF investor_presentation
Breakthroughs that change patients' lives ® February 8, 2022Fourth Quarter 2021 Earnings Teleconference
Breakthroughs that change patients' lives ®
February 8, 2022Fourth Quarter 2021
Earnings Teleconference Introduction
Senior Vice President,
Chief Investor Relations Officer 3
Fourth Quarter 2021 EarningsForward -Looking Statements and Non- GAAP Financial Information
Our discussions during this conference call will include forward- looking statements that are subject to substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such statements. We include forward- looking statements about, among other topics, our anticipated operating
and financial performance, reorganizations, business plans and prospects, expectations for our product pipeline, in- line product s and product candidates, including
anticipated regulatory submissions, data read- outs, study starts, approvals, clinical trial results and other developing data, r evenue contribution, growth, performance,
timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, dividends and share repurchas es,plans for and prospects of our acquisitions,
dispositions and other business development activities, and our ability to successfully capitalize on these opportunities, manuf acturing and product supply, our efforts to
respond to COVID -19, including Comirnaty and our oral COVID -19 treatment (Paxlovid), our expectations regarding the impact of CO VID-19 on our business,
operations and financial results, and our Environmental, Social and Governance strategy. Among other things, statements regar ding revenue and earnings per share
growth; the development or commercial potential of our product pipeline, in- line products, product candidates and additional indications, including expected clinical trial
protocols, the timing of the initiation and progress of clinical trials and data read- outs from trials; the timing for the submi ssion of applications for and receipt of
regulatory approvals; and expected breakthrough, best or first -in-class or blockbuster status of our medicines or vaccines are f orward -looking and are estimates that
are subject to change and clinical trial and regulatory success. These statements are subject to risks, uncertainties and other factors that may cause actual results to
differ materially from past results, future plans and projected future results. Additional information regarding these and ot herfactors can be found in Pfizer’s Annual
Report on Form 10- K for the fiscal year ended December 31, 2020 and its subsequent reports on Form 10- Q, including in the sections thereof captioned “Risk Factors”
and “Forward- Looking Information and Factors That May Affect Future Results”, as well as in our subsequent reports on Form 8- K, all of which are filed with the U.S.
Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com . Potential risks and uncertainties also include the impact of COVID -19 on our
Preview truncated — download the full document for the complete content.
investor_presentation
129 Pages
investor_presentation
30 Pages
Faraday Copper